Document is current

Article History

Received: 7 January 2026

Accepted: 14 April 2026

First Online: 17 May 2026

Declarations

:

: Melinda Gooderham has been an investigator, speaker, and/or advisor for: AbbVie, Amgen, Akros, AnaptysBio, Apogee, Arcutis, Aristea, Bausch Health, BMS, Boehringer Ingelheim, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma A/S, MedImmune, Merck, Meiji, Moonlake, Novartis, Oruka, Pfizer, Q32 Bio, Reistone, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne. Christopher G. Bunick has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Takeda, Timber, and Palvella; a consultant for AbbVie, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Connect BioPharma, Dermavant, Eli Lilly, EPI Health/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, Teladoc, Triveni, and UCB. Christopher G. Bunick is an Editorial Board member of Dermatology and Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. JiaDe Yu has served as a consultant/advisory board/investigator for the following: Abbvie, Arcutis, Astria, Dermavant, iRhythm, LEO Pharma A/S, Lilly, National Eczema Association, O’Glacee, Pfizer, Sanofi, Smartpractice, Sol–Gel; and also receives honorarium from UptoDate. Douglas Maslin, Marie Louise Østerdal, Anders Søhoel, and Daniel Elenius Madsen are employees of LEO Pharma A/S. Shannon K.R. Schneider is an employee of LEO Pharma Inc. Lawrence F. Eichenfield has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, Dermavant, Eli Lilly, Forte, Galderma, Incyte, Janssen, Johnson & Johnson, LEO Pharma A/S, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi-Genzyme, Takeda, Target RWE, and UCB.

: Trial protocols were approved by all relevant ethics committees and institutional review boards (DELTA 2, see [ ]; phase 1 AD trial, see Electronic Supplementary Material Table ). The trials were conducted according to the principles of the Declaration of Helsinki and the International Council on Harmonization Guidelines for Good Clinical Practice and conformed with all relevant country-specific laws and regulations. All patients, or their legal representatives, provided written informed consent. In DELTA 2, patients at selected trial sites had the additional option to participate in a photography component to capture disease status over time; participating patients were required to provide additional informed consent, including consent for their photographs to be published for scientific and/or commercial purposes.